Arrowhead Pharmaceuticals Balance Sheet
NASDAQ: ARWRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Arrowhead Pharmaceuticals financial position
At the end of fiscal 2025, Arrowhead Pharmaceuticals reported total assets of $1.39 billion, up 21.5% from a year earlier against total liabilities of $881.9 million. Shareholders' equity stood at $466.1 million, or 33.6% of assets. The company held $226.5 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 4.86, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Arrowhead Pharmaceuticals balance sheet (annual)
| Fiscal year (USD) | FY 20252025-09-30 | FY 20242024-09-30 | FY 20232023-09-30 | FY 20222022-09-30 | FY 20212021-09-30 | FY 20202020-09-30 | FY 20192019-09-30 | FY 20182018-09-30 | FY 20172017-09-30 | FY 20162016-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 226.55M | 102.69M | 110.89M | 108.00M | 184.43M | 143.58M | 221.80M | 30.13M | 24.84M | 85.37M |
| Short-Term Investments | 692.82M | 578.28M | 292.74M | 0 | 126.73M | 85.02M | — | — | — | — |
| Receivables | 6.82M | 0 | 0 | 1.41M | 10.26M | 846.00K | 661.36K | 327.38K | 67.80K | 75.00K |
| Total Current Assets | 950.64M | 695.47M | 416.47M | 405.30M | 384.60M | 322.37M | 265.25M | 78.77M | 67.90M | 90.50M |
| Property, Plant & Equipment | 382.51M | 386.03M | 290.26M | 110.30M | 48.67M | 30.88M | 23.21M | 13.94M | 15.51M | 15.39M |
| Intangible Assets | 6.86M | 8.56M | 10.26M | 11.96M | 13.66M | 15.36M | 17.06M | 18.76M | 20.46M | 22.16M |
| Total Assets | 1.39B | 1.14B | 765.55M | 691.94M | 710.15M | 522.50M | 349.85M | 111.61M | 104.02M | 128.18M |
| Accounts Payable | 17.67M | 11.39M | 35.87M | 2.87M | 9.46M | 6.83M | 7.65M | 2.81M | 4.08M | 12.23M |
| Total Current Liabilities | 195.49M | 103.17M | 105.46M | 138.85M | 146.54M | 40.68M | 97.07M | 12.36M | 18.70M | 25.64M |
| Long-Term Debt | — | — | — | — | — | — | — | 2.10M | 2.33M | 2.53M |
| Total Liabilities | 881.88M | 948.74M | 478.39M | 273.60M | 301.33M | 60.73M | 105.81M | 16.37M | 23.16M | 33.15M |
| Shareholders' Equity | 466.05M | 185.44M | 271.34M | 398.52M | 408.82M | 461.78M | 244.59M | 95.80M | 81.42M | 95.58M |
| Retained Earnings | -1.63B | -1.63B | -1.03B | -820.75M | -644.69M | -503.84M | -419.29M | -487.27M | -432.82M | -398.44M |
| Total Debt | — | — | — | — | — | — | — | 2.10M | 2.33M | 2.53M |
| Net Cash (Debt) | 919.37M | 680.96M | 403.63M | 108.00M | 311.16M | 228.60M | 221.80M | 28.03M | 22.51M | 82.83M |
| Shares Outstanding | 135.70M | 124.38M | 107.31M | 105.96M | 104.33M | 102.38M | 95.51M | 88.51M | 74.79M | 69.75M |
This table shows 10 annual periods of Arrowhead Pharmaceuticals's balance sheet, from FY 2025 back to FY 2016, across 17 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow ARWR's reporting calendar. What is a balance sheet?